Review paper<BR>Leflunomide safety profile

Bożena Targońska-Stępniak

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2008
vol. 46

Send email

Copy url:

abstract:

Review paper
Leflunomide safety profile

Bożena Targońska-Stępniak

Reumatologia 2008; 46, 6: 367–371

Online publish date: 2009/01/21

View full text Get citation

Leflunomide (LEF) is one of the disease-modifying antirheumatic drugs (DMARDs) used in the treatment of rheumatoid and psoriatic arthritis. Results of clinical trials and post-marketing studies documented that LEF is effective in reducing disease activity and improving quality of life. The safety data show no increased risk of adverse events during LEF treatment, in comparison with other DMARDs. The incidence of adverse events during LEF therapy is not significantly different from that observed with methotrexate or sulfasalazine treatment. The most common LEF-associated adverse events include: diarrhoea, elevated liver enzymes, alopecia and rash. Adverse events are usually observed during the first 1-3 months of therapy. Careful monitoring of liver function tests and complete blood cell count is necessary during LEF therapy, especially within the first
6 months of treatment.

keywords:

disease-modifying antirheumatic drugs, leflunomide, arthritis, safety

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

Review paperLeflunomide safety profile

Bożena Targońska-Stępniak

disease-modifying antirheumatic drugs, leflunomide, arthritis, safety

Review paper
Leflunomide safety profile